Committed to our customers and benefit for patients
Immedica has developed a well-tailored and efficient approach for the successful management of rare disease products, including orphan drugs. In optimizing access to the products, we offer a package of complete commercial pharmaceutical services and strategies including marketing and sales via an experienced rare disease field force, navigation of the complex pricing and reimbursement environment, tender management, regulatory and medical affairs, drug safety and quality assurance. Immedica also runs an effective logistics chain for distribution of products, all over Europe and the Middle East. We have long-established relations and networks with key opinion leaders and other stakeholders across the rare disease areas.
Immedica always puts the patients first, and in a partnership, assets get full commitment and support in order for us to bring the valuable medicines to patients. Our principal philosophy is that everything we do should add value for our customers, partners and most importantly the patients. Immedica’s senior leadership has a long and proven track record of operating in mutually fruitful commercial partnerships, and our company possesses extensive experience from, and flexibility on, different partnership structures. Immedica is continuously searching for new products which could support in fulfilling unmet medical needs in Europe and the Middle East.
Immedica was formed 2018 through the acquisition of an existing platform (Medical Need Europe) along with new management and key employees. Immedica is focused on fulfilling unmet medical needs in specialty healthcare
– Niche specialty pharmaceuticals
– Orphan drugs
Capabilities for registration, distribution, marketing and sale of pharmaceuticals across Europe and the Middle East
– No in‐house research or development
– Headquartered in Stockholm, Sweden
Privately held, owned by management team and Impilo AB.
Rare disease facts and figures
|1 in 10||People are affected by rare diseases|
|1 in 2||Rare diseases don’t have a foundation or research support group|
|1 of 2||Patients diagnosed with a rare disease is a child|
|3 of 10||Children with a rare disease won’t live to see their 5th birthday|
|350||Million people suffer from a rare disease globally|
|8 in 10||Rare diseases are caused by a faulty gene|
|8 years||Average time it takes for rare patients to receive an accurate diagnosis|
|95%||Of rare diseases lack an FDA approved treatment|
|RARE||Diseases impact more people than cancer and AIDS Combined|
|7000||Types of rare diseases|
Backed by Impilo since 2018
Immedica is owned by Impilo AB and its management team. Impilo is a Stockholm-based investment company focused solely on investments in Nordic healthcare companies operating in pharmaceuticals, medical technology, healthcare services and other health-related industries. Impilo has SEK 3.6 bn in long-term capital commitments from highly reputable Nordic and international family offices and institutions, including i.a. funds managed by Goldman Sachs Asset Management, the National Pension Fund in Sweden, AP3, and TryghedsGruppen in Denmark.